Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Analysis of Changes in Medication Prescriptions After Hospitalization for 4 Disciplines: Gerontology, Diabetology, Cardiology and Rheumatology: Medical, Pharmaceutical and Economic Aspects (PHMEV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03371303
Recruitment Status : Active, not recruiting
First Posted : December 13, 2017
Last Update Posted : December 13, 2017
Sponsor:
Information provided by (Responsible Party):
Assistance Publique Hopitaux De Marseille

Brief Summary:
The modifications of the medicinal treatments secondary to the hospitalizations have multiple reasons: reassessment of the previous treatment (conciliation), new therapeutic necessities, potential risk of iatrogeny or of drug interaction, restrictions of the therapeutic booklet, classification in reserve or hospital prescription ... These modifications are potentially generating extra costs for the Health Insurance and are monitored under the terms of the Contract of Good Use. The aims of this analysis are to define the medical-pharmaceutical rationale of the treatment changes imposed by hospitalization in a university-hospital center, their influence on the security of the medical treatment of patients and their financial implications for healthcare organizations

Condition or disease Intervention/treatment
Diabetes Cardiac Disease Rheumatic Diseases Other: collection of prescription data

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 400 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 6 Months
Official Title: Analysis of Changes in Medication Prescriptions After Hospitalization for 4 Disciplines: Gerontology, Diabetology, Cardiology and Rheumatology: Medical, Pharmaceutical and Economic Aspects
Actual Study Start Date : November 1, 2017
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : February 2021

Group/Cohort Intervention/treatment
diabetology Other: collection of prescription data
collection of prescription data before and after a hospitalization

cardiology Other: collection of prescription data
collection of prescription data before and after a hospitalization

rheumatology Other: collection of prescription data
collection of prescription data before and after a hospitalization

geriatrics Other: collection of prescription data
collection of prescription data before and after a hospitalization




Primary Outcome Measures :
  1. entry orders before hospitalization [ Time Frame: 15 months ]
  2. exit orders after hospitalization [ Time Frame: 15 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients must be hospitalized in one of the services of a university hospital, in the following 4 disciplines: diabetology, geriatrics, cardiology and rheumatology
Criteria

inclusion criteria

  • Patient social insured
  • Patient belonging to the general social security scheme
  • Patient followed in cardiology, rheumatology, geriatrics or diabetology departments

no exclusion criteria


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03371303


Locations
Layout table for location information
France
Assistance Publique Hôpitaux de Marseille
Marseille, France, 13005
Sponsors and Collaborators
Assistance Publique Hopitaux De Marseille
Additional Information:

Layout table for additonal information
Responsible Party: Assistance Publique Hopitaux De Marseille
ClinicalTrials.gov Identifier: NCT03371303    
Other Study ID Numbers: 2016-25
First Posted: December 13, 2017    Key Record Dates
Last Update Posted: December 13, 2017
Last Verified: December 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Rheumatic Diseases
Heart Diseases
Collagen Diseases
Musculoskeletal Diseases
Connective Tissue Diseases
Cardiovascular Diseases